Laura Andrews, MD
Endocrinology, Diabetes & Metabolism · Menasha, WINPI 1548254535
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $262,100 of the $293,698 with a category attached, or 89.2%. 13 manufacturers reported payments, led by Novo Nordisk at 37.2% of the total. Among endocrinology, diabetes & metabolism clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $637.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$109K
- Sanofi-aventis U.S. LLC$55K
- Dexcom, Inc.$42K
- Lilly USA, LLC$28K
- Boehringer Ingelheim$26K
- AstraZeneca$26K
- plus $7K from 7 others
What the payments were for
- Consulting fees$7,4303%
- Speaking & faculty fees$262,10089%
- Travel & lodging$14,6965%
- Food & beverage$9,4213%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 113 | $109,134 |
| Sanofi-aventis U.S. LLC | 68 | $55,497 |
| Dexcom, Inc. | 57 | $41,791 |
| Lilly USA, LLC | 42 | $27,989 |
| Boehringer Ingelheim | 57 | $26,269 |
| AstraZeneca | 35 | $26,108 |
| Medtronic(2 entities) | 73 | $6,399 |
| BETA Bionics, Inc. | 6 | $222 |
| Abbott | 5 | $201 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| GSK | 1 | $27 |
| Insulet Corporation | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$53,213
- Ozempic$50,485
- RYBELSUS$37,824
- TZIELD$33,961
- DEXCOM G7 GSS (161)$31,811
- FARXIGA$25,299
- SOLIQUA 100/33$14,315
- DEXCOM STELO GLUCOSE BIOSENSOR$14,078
- TOUJEO$12,094
- DEXCOM G6 TRANSMITTER$9,384
- Tresiba$7,014
- Victoza$5,230
- MINIMED 780G$4,612
- Minimed 670G System$712
- FreeStyle Libre$142
How this compares
$293,698 in reported general payments places this provider in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 349 | $270,941 |
| OzempicSemaglutide | 202 | $238,034 |
| Humalog Kwikpen U-200Insulin Lispro | 65 | $183,689 |
| TrulicityDulaglutide | 137 | $161,146 |
| Tresiba Flextouch U-200Insulin Degludec | 69 | $136,033 |
| MounjaroTirzepatide | 104 | $123,502 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 99 | $116,078 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 90 | $88,481 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 448 | $78,534 |
| Tresiba Flextouch U-100Insulin Degludec | 85 | $64,419 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 42 | $62,119 |
| Humulin R U-500Insulin Regular, Human | 27 | $54,731 |
| Humalog Kwikpen U-100Insulin Lispro | 162 | $53,944 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $49,877 |
| FarxigaDapagliflozin Propanediol | 50 | $43,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $27,989 | $298,406280 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $26,269 | $288,950370 claims |
| Novo NordiskOzempic, Novolog, Novolog Mix 70-30 | $109,134 | $254,889252 claims |
| AstraZenecaFarxiga | $26,108 | $43,94350 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $55,497 | $24,83053 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Menasha
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Vinay PatelNeenah$64K
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
- Adriana IoachimescuMilwaukee$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.